Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parenteral Ascorbic Acid Repletion in Transplantation (PARTI)
NCT04756063Phase 4Withdrawn
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2026
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ascorbic acid in liver graft failure (LGF), Liver transplant rejection, sponsored by University of Wisconsin–Madison. Planned start Sep 2026; status: withdrawn.
02
Drugs
ascorbic acid
03
Conditions
liver graft failure (LGF)Liver transplant rejection
Beyond the preview
Go deeper on NCT04756063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756063.